Literature DB >> 8680543

Hepatic transport of serum bilirubin, bromsulfophthalein, and indocyanine green in patients with congenital non-hemolytic hyperbilirubinemia and patients with constitutional indocyanine green excretory defect.

M Nambu1, T Namihisa.   

Abstract

We carried out a retrospective study of 71 patients with congenital non-hemolytic hyperbilirubinemia who had been treated at our institution over the 25 years from 1965 to 1990. Twenty patients had Gilbert's syndrome, 1 had Crigler-Najjar syndrome, 1 had new type unconjugated hyperbilirubinemia, 21 had Dubin-Johnson syndrome, and 28 had Rotor's syndrome. We also reviewed 20 patients with constitutional indocyanine green (ICG) excretory defect. The study focused on the hepatic transport of serum bilirubin, bromsulfophthalein (BSP), and ICG. In Dubin-Johnson syndrome, a defect appeared in late-stage transport, while uptake and storage capacity were normal. In Rotor's syndrome, defects were found in the early stage, and storage capacity was reduced, while excretion into bile was slightly suppressed. A secondary rise in serum ICG was seen in 5 of the 10 patients with Dubin-Johnson syndrome. The transport defect in Gilbert's syndrome was unclear. It could not be considered to be homogeneous, but it may exist at multiple sites, from the conjugation with serum proteins to excretion into bile. Following phenobarbital administration, the ICG secondary rise in the 5 patients with Dubin-Johnson syndrome disappeared, and ICG was rapidly cleared from blood. However, in patients with Dubin-Johnson syndrome, BSP clearance in serum did not show any change before and after phenobarbital administration. ICG excretion in patients with constitutional ICG excretory defect was due only to the impairment o ICG transport, and the defect was suggested to be hepatic uptake. These results indicate that studies of the hepatic transport of bilirubin, BSP, and ICG are useful for determining the etiological factors involved in congenital hyperbilirubinemia and constitutional ICG excretory defect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8680543     DOI: 10.1007/bf02389522

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  20 in total

1.  The transfer of bromsulphthalein from the plasma to the bile in man.

Authors:  G BARBER-RILEY; A E GOETZEE; T G RICHARDS; J Y THOMSON
Journal:  Clin Sci       Date:  1961-04       Impact factor: 6.124

2.  Studies of chronic familial non-hemolytic jaundice with conjugated bilirubin in the serum with and without an unidentified pigment in the liver cells.

Authors:  I M ARIAS
Journal:  Am J Med       Date:  1961-10       Impact factor: 4.965

3.  Familial nonhemolytic jaundice with conjugated bilirubin in the serum; a case study.

Authors:  L SCHIFF; B H BILLING; Y OIKAWA
Journal:  N Engl J Med       Date:  1959-06-25       Impact factor: 91.245

4.  Rotor's and Dubin-Johnson syndromes.

Authors:  T Namihisa; M Nambu
Journal:  N Engl J Med       Date:  1977-09-08       Impact factor: 91.245

5.  Effect of phenobarbital on liver functions in patients with Dubin-Johnson syndrome.

Authors:  M Shani; U Seligsohn; J Ben-Ezzer
Journal:  Gastroenterology       Date:  1974-08       Impact factor: 22.682

6.  Hepatic handling of unconjugated dyes in the Dubin-Johnson syndrome.

Authors:  S Erlinger; D Dhumeaux; J F Desjeux; J P Benhamou
Journal:  Gastroenterology       Date:  1973-01       Impact factor: 22.682

7.  Metabolism of the bromsulphalein in Dubin-Johnson syndrome. Diagnostic value of the paradoxical increase in plasma levels at BSP.

Authors:  J Rodes; A Zubizarreta; M Bruguera
Journal:  Am J Dig Dis       Date:  1972-06

8.  A nonhuman primate model of Gilbert's syndrome.

Authors:  O W Portman; J Roy Chowdhury; N Roy Chowdhury; M Alexander; C E Cornelius; I M Arias
Journal:  Hepatology       Date:  1984 Mar-Apr       Impact factor: 17.425

9.  Marked delay in indocyanine green plasma clearance with a near-normal bromosulphophthalein retention test: a constitutional abnormality?

Authors:  K Okuda; H Ohkubo; H Musha; K Kotoda; H Abe; K Tanikawa
Journal:  Gut       Date:  1976-08       Impact factor: 23.059

10.  Biliary transport and hepatic storage of sulfobromophthalein sodium in the unanesthetized dog, in normal man, and in patients with hepatic disease.

Authors:  H O WHEELER; J I MELTZER; S E BRADLEY
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

View more
  5 in total

1.  Hepatectomy in a hepatocellular carcinoma case with Dubin-Johnson syndrome and indocyanine green excretory defect.

Authors:  Hideki Aoki; Toshiaki Morihiro; Takashi Arata; Nobuhiko Kanaya; Shou Takeda; Takayuki Ninomiya; Masayuki Seita; Kou Katsuda; Kohji Tanakaya; Hitoshi Takeuchi
Journal:  Clin J Gastroenterol       Date:  2012-12-06

2.  Quantified Risk Assessment for Major Hepatectomy via the Indocyanine Green Clearance Rate and Liver Volumetry Combined with Standard Liver Volume.

Authors:  Shin Hwang; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Chul-Soo Ahn; Deok-Bog Moon; Ki-Hun Kim; Young-Joo Lee; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2015-05-07       Impact factor: 3.452

3.  Reliability of indocyanine green retention and clearance rates at 15 minutes calculated by dye-dilution cardiac output flowmetry in comparison to blood sampling in patients undergoing hepatic resection.

Authors:  Masahide Hiyoshi; Koichi Yano; Atsushi Nanashima; Naoya Imamura; Takeomi Hamada; Takashi Wada
Journal:  Indian J Gastroenterol       Date:  2019-12-05

4.  Hepatectomy in a case of hepatocellular carcinoma with constitutional indocyanine green excretory defect.

Authors:  Richi Nakatake; Morihiko Ishizaki; Chika Miyasaka; Kosuke Matsui; Masaki Kaibori
Journal:  Int J Surg Case Rep       Date:  2018-11-01

5.  Quantitative Assessment of the Portal Pressure for the Liver Surgery Using Serological Tests.

Authors:  Taegyu Kim; Bong-Wan Kim; Hee-Jung Wang; Hyun Young Lee; Je Hwan Won; Jinoo Kim; Xu-Guang Hu; Joohyun Sim; Jun Bae Bang; Young Bae Kim
Journal:  Ann Surg       Date:  2016-08       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.